TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05485961: A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage

Sponsor: CSL Behring · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 3110 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,085,496

Rescue Site Savings

+$6,642,656

Unlock Full NCT05485961 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05485961 Rescue Dossier →